ArticleOncotarget2017
Development of mesenchymal subtype gene signature for clinical application in gastric cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Systematic Review of Prognostic Gene Signature in Gastric Cancer Patients.Frontiers in bioengineering and biotechnology · 2020Pooled it
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.Nature medicine · 2018Trial
- Article
- Article
- The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting.Frontiers in cell and developmental biology · 2023Review
- Review
- Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer.Scientific reports · 2022Article
- Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.Pharmacogenomics · 2021Review
- Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer.Experimental & molecular medicine · 2020Article
- An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer.Oncoimmunology · 2020Article
- Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer.Cancers · 2020Article
- Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells.Clinical & translational immunology · 2020Article
- First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.Therapeutic advances in medical oncology · 2020Article
- Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray.PloS one · 2020Article
- Dissection of gastric cancer heterogeneity for precision oncology.Cancer science · 2019Review
- Clinical Implementation of Precision Medicine in Gastric Cancer.Journal of gastric cancer · 2019Review
- Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue.Scientific reports · 2019Article
- Identification and validation of a Hedgehog pathway-based 3-gene prognostic signature for gastric cancers.Oncology letters · 2018Article
- Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making?World journal of gastrointestinal oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, in the Asian Cancer Research Group (ACRG) project, we defined four distinct molecular subtypes in gastric cancer (GC). Mesenchymal (microsatellite stable with epithelial-to-mesenchymal transition phenotype, MSS/EMT) tumors showed the worst prognosis among all the subtypes. To develop a gene signature for predicting mesenchymal subtype GC, we conducted gene expression profiling using a NanoString assay in 70 ACRG specimens. The gene signature was validated in an independent set obtained from the prospective Adjuvant chemoRadioTherapy In Stomach Tumor (ARTIST) trial. The association between the mesenchymal subtype and survival was investigated. After cross-platform concordance test performed in 70 ACRG specimens, a 71-gene MSS/EMT signature was obtained. In the validation set, the gene signature predicted that 20 of 73 (27%) patients had mesenchymal tumors. Patients with mesenchymal subtype had diffuse GC, poorly-differentiated or signet ring cell carcinoma, and were microsatellite stable. The estimated hazard ratio for survival in patients with mesenchymal GC compared to those with non-mesenchymal tumors was 2.262 (95% confidence interval, 1.410 to 3.636; P=0.001). The survival difference remained significant when the subtypes were analyzed according to clinical prognostic parameters. This study suggested that the NanoString-based 71-gene signature for mesenchymal subtype is a strong predictor of the outcome in patients with GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.